Kineret® approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Health Canada has approved Kineret® (anakinra) for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) in adults, adolescents, children and infants aged eight months and older with a body weight of 10 kg or above. Kineret is already approved in Canada for active rheumatoid arthritis (RA) in patients 18 years of age or older. “We are very happy to receive the NOMID indication approval from Health Canada. NOMID is a severe inflammatory disease which is associated with chronic